JP2015533490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533490A5 JP2015533490A5 JP2015532046A JP2015532046A JP2015533490A5 JP 2015533490 A5 JP2015533490 A5 JP 2015533490A5 JP 2015532046 A JP2015532046 A JP 2015532046A JP 2015532046 A JP2015532046 A JP 2015532046A JP 2015533490 A5 JP2015533490 A5 JP 2015533490A5
- Authority
- JP
- Japan
- Prior art keywords
- binding polypeptide
- residue
- glycan
- domain
- numbering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 150000004676 glycans Chemical class 0.000 claims 11
- 239000012636 effector Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 8
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 125000005629 sialic acid group Chemical group 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 239000002619 cytotoxin Substances 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 101710112752 Cytotoxin Proteins 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 125000003172 aldehyde group Chemical group 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 150000002923 oximes Chemical class 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930182830 galactose Chemical group 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/003819 WO2013037484A2 (en) | 2011-09-12 | 2012-09-12 | Anti-aplhabetatcr antibody |
| EPPCT/EP2012/003819 | 2012-09-12 | ||
| US201361776715P | 2013-03-11 | 2013-03-11 | |
| US61/776,715 | 2013-03-11 | ||
| PCT/US2013/059481 WO2014043361A1 (en) | 2012-09-12 | 2013-09-12 | Fc containing polypeptides with altered glycosylation and reduced effector function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533490A JP2015533490A (ja) | 2015-11-26 |
| JP2015533490A5 true JP2015533490A5 (enExample) | 2016-10-20 |
| JP6438397B2 JP6438397B2 (ja) | 2018-12-12 |
Family
ID=50278674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532046A Active JP6438397B2 (ja) | 2012-09-12 | 2013-09-12 | 変更されたグリコシル化および低減されたエフェクター機能を有するＦｃ含有ポリペプチド |
Country Status (34)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US9701753B2 (en) | 2013-03-11 | 2017-07-11 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
| WO2015143091A1 (en) * | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| AU2015243512B2 (en) | 2014-04-08 | 2020-06-04 | University Of Georgia Research Foundation Inc. | Site-specific antibody-drug glycoconjugates and methods |
| WO2015191883A1 (en) * | 2014-06-12 | 2015-12-17 | Dophen Biomedical | Homogenous antibody drug conjugates via enzymatic methods |
| CA3205824A1 (en) * | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3222292A1 (en) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| LT3538554T (lt) | 2016-11-08 | 2025-10-10 | Antigeną surišantys baltymai, antagonizuojantys leptino receptorius | |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| GB201717446D0 (en) | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
| SG11202005146VA (en) | 2017-12-18 | 2020-06-29 | Regeneron Pharma | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| PT3773713T (pt) | 2018-04-06 | 2025-07-29 | Regeneron Pharma | Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia |
| JP1640846S (enExample) * | 2018-10-16 | 2019-09-09 | ||
| CA3110377A1 (en) | 2018-11-21 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Anti-staphylococcus antibodies and uses thereof |
| PH12021551476A1 (en) | 2018-12-21 | 2022-04-25 | Regeneron Pharma | Rifamycin analogs and antibody-drug conjugates thereof |
| WO2020160242A1 (en) | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| CN114096559B (zh) * | 2019-03-27 | 2026-03-20 | 蒂嘉特克斯公司 | 工程化iga抗体及其使用方法 |
| CN120192414A (zh) | 2019-04-03 | 2025-06-24 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| KR20230069969A (ko) | 2020-09-15 | 2023-05-19 | 리제너론 파마슈티칼스 인코포레이티드 | 통증에 대한 lepr 아고니스트의 사용 |
| KR20220052098A (ko) | 2020-10-20 | 2022-04-27 | 주식회사 엘지에너지솔루션 | 마스킹 테이프를 이용한 전극 시편에 대한 물성 측정 시스템 및 이를 이용한 물성 측정 방법 |
| KR102576252B1 (ko) * | 2021-04-07 | 2023-09-11 | 아주대학교산학협력단 | 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물 |
| TW202325273A (zh) * | 2021-10-22 | 2023-07-01 | 美商杜夫特學院信託管理公司 | 靶向fap之中子捕獲劑及與其相關之用途及調配物 |
| KR20250058123A (ko) | 2022-07-29 | 2025-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 항-TfR:페이로드 융합 및 이의 사용 방법 |
| CA3263388A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | VIRAL PARTICLES RETRIBUTED TO TRANSFERRIN RECEPTOR 1 |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| EP4612184A1 (en) | 2022-11-04 | 2025-09-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| AU2023379451A1 (en) | 2022-11-14 | 2025-05-01 | Regeneron Pharmaceuticals, Inc. | Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof |
| KR20250116795A (ko) | 2022-11-14 | 2025-08-01 | 리제너론 파마슈티칼스 인코포레이티드 | 별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법 |
| IL325163A (en) | 2023-06-16 | 2026-02-01 | Regeneron Pharma | CD40 × CD40 dual-specific antigen-binding molecules and their application |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
| TW202535925A (zh) | 2023-10-25 | 2025-09-16 | 比利時商艾伯霖克斯公司 | 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體 |
| TW202540169A (zh) | 2023-11-08 | 2025-10-16 | 法商賽諾菲公司 | 基於ｃｄ２５的溶酶體降解物及其用途 |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| EP4616869A1 (en) * | 2024-03-15 | 2025-09-17 | Oncomatryx Biopharma, S.L. | Fap targeted antibody-drug conjugates |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| DE69738522T2 (de) | 1996-08-02 | 2009-04-02 | Bristol-Myers Squibb Co. | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| DK1641823T3 (da) * | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| US8399618B2 (en) * | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| SI1706424T1 (sl) | 2004-01-12 | 2010-01-29 | Applied Molecular Evolution | Variante fc regij |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| WO2006036922A2 (en) * | 2004-09-27 | 2006-04-06 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するＦｃ変異体 |
| BRPI0611445A2 (pt) * | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| PT1896071E (pt) | 2005-06-30 | 2015-07-09 | Janssen Biotech Inc | Métodos e composições com melhorias na atividade terapêutica |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8460364B2 (en) | 2006-07-20 | 2013-06-11 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
| EP2125893A2 (en) * | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US20110137011A1 (en) * | 2008-04-21 | 2011-06-09 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
| MX352889B (es) * | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| UY34317A (es) * | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
-
2013
- 2013-09-12 PL PL18166377.4T patent/PL3366705T3/pl unknown
- 2013-09-12 KR KR1020157009038A patent/KR102185151B1/ko active Active
- 2013-09-12 PT PT13766833T patent/PT2895513T/pt unknown
- 2013-09-12 HU HUE18166377A patent/HUE062876T2/hu unknown
- 2013-09-12 EP EP23164492.3A patent/EP4223783A3/en active Pending
- 2013-09-12 KR KR1020207033737A patent/KR102426488B1/ko active Active
- 2013-09-12 SI SI201331144T patent/SI2895513T1/sl unknown
- 2013-09-12 SG SG11201501521TA patent/SG11201501521TA/en unknown
- 2013-09-12 HU HUE13766833A patent/HUE039337T2/hu unknown
- 2013-09-12 CA CA2884762A patent/CA2884762C/en active Active
- 2013-09-12 SI SI201332053T patent/SI3366705T1/sl unknown
- 2013-09-12 MY MYPI2015000513A patent/MY170126A/en unknown
- 2013-09-12 DK DK18166377.4T patent/DK3366705T5/da active
- 2013-09-12 ES ES13766833.1T patent/ES2684549T3/es active Active
- 2013-09-12 EP EP13766833.1A patent/EP2895513B1/en active Active
- 2013-09-12 EP EP18166377.4A patent/EP3366705B1/en active Active
- 2013-09-12 PE PE2015000327A patent/PE20150650A1/es active IP Right Grant
- 2013-09-12 SG SG10201701831VA patent/SG10201701831VA/en unknown
- 2013-09-12 HR HRP20181354TT patent/HRP20181354T1/hr unknown
- 2013-09-12 DK DK13766833.1T patent/DK2895513T3/en active
- 2013-09-12 FI FIEP18166377.4T patent/FI3366705T3/fi active
- 2013-09-12 WO PCT/US2013/059481 patent/WO2014043361A1/en not_active Ceased
- 2013-09-12 PL PL13766833T patent/PL2895513T3/pl unknown
- 2013-09-12 LT LTEP18166377.4T patent/LT3366705T/lt unknown
- 2013-09-12 HR HRP20230623TT patent/HRP20230623T1/hr unknown
- 2013-09-12 EA EA202091166A patent/EA202091166A1/ru unknown
- 2013-09-12 RS RS20180981A patent/RS57748B1/sr unknown
- 2013-09-12 PT PT181663774T patent/PT3366705T/pt unknown
- 2013-09-12 JP JP2015532046A patent/JP6438397B2/ja active Active
- 2013-09-12 CN CN201380058863.8A patent/CN104797601B/zh active Active
- 2013-09-12 LT LTEP13766833.1T patent/LT2895513T/lt unknown
- 2013-09-12 KR KR1020227025572A patent/KR20220110855A/ko not_active Ceased
- 2013-09-12 AU AU2013315499A patent/AU2013315499B2/en active Active
- 2013-09-12 RS RS20230536A patent/RS64317B1/sr unknown
- 2013-09-12 NZ NZ705983A patent/NZ705983A/en unknown
- 2013-09-12 CN CN201910721123.7A patent/CN110590953A/zh active Pending
- 2013-09-12 EA EA201590545A patent/EA035987B1/ru unknown
- 2013-09-12 MA MA37949A patent/MA37949B1/fr unknown
- 2013-09-12 MX MX2015003234A patent/MX366103B/es active IP Right Grant
- 2013-09-12 ES ES18166377T patent/ES2950509T3/es active Active
- 2013-12-09 UA UAA201503410A patent/UA116995C2/uk unknown
-
2015
- 2015-03-02 ZA ZA2015/01417A patent/ZA201501417B/en unknown
- 2015-03-05 DO DO2015000050A patent/DOP2015000050A/es unknown
- 2015-03-06 TN TNP2015000085A patent/TN2015000085A1/fr unknown
- 2015-03-09 IL IL237640A patent/IL237640B/en active IP Right Grant
- 2015-03-11 PH PH12015500528A patent/PH12015500528A1/en unknown
- 2015-03-11 CL CL2015000606A patent/CL2015000606A1/es unknown
- 2015-03-12 MX MX2019007753A patent/MX2019007753A/es unknown
- 2015-03-19 CR CR20150147A patent/CR20150147A/es unknown
- 2015-04-10 EC ECIEPI201514133A patent/ECSP15014133A/es unknown
-
2018
- 2018-08-23 CY CY181100880T patent/CY1120909T1/el unknown
-
2019
- 2019-11-28 IL IL271027A patent/IL271027B/en active IP Right Grant
-
2020
- 2020-08-23 IL IL276866A patent/IL276866B/en unknown
-
2021
- 2021-09-29 IL IL286766A patent/IL286766A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533490A5 (enExample) | ||
| JP2016512425A5 (enExample) | ||
| JP2016512426A5 (enExample) | ||
| RU2015143057A (ru) | Гипергликозилированные связывающие полипептиды | |
| WO2011091078A3 (en) | Antibody fc variants with enhanced complement activity | |
| HRP20230623T1 (hr) | Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom | |
| JP2014508759A5 (enExample) | ||
| HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
| WO2006023403A3 (en) | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity | |
| WO2008090959A1 (ja) | エフェクター活性が増強された遺伝子組換え抗体組成物 | |
| EA201070739A1 (ru) | Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и связанные с ними способы | |
| JP2011173914A5 (enExample) | ||
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| IL199263A (en) | Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation | |
| WO2013151672A3 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
| CN106413749B (zh) | 新颖全谱抗登革抗体 | |
| JP2017527272A5 (enExample) | ||
| NZ584893A (en) | PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF | |
| JP2015078191A5 (enExample) | ||
| JP2014221758A5 (enExample) | ||
| JP2012034692A5 (enExample) | ||
| WO2013115926A3 (en) | Aspartyl-trna synthetase-fc conjugates | |
| JP2016531852A5 (enExample) | ||
| US20250163125A1 (en) | Lfa3 variants and compositions and uses thereof | |
| CA2633080A1 (en) | Method for preparing antibodies selective for activating fc receptors |